Clinical

An analysis of challenges and strategies for integrating HER2-directed therapies into decision-making for NSCLC, with a focus on timely updates, collaborative efforts among stakeholders, and balancing equitable access with cost management.

An overview of challenges in transitioning from IV to oral medications and guidance on identifying NSCLC patient populations most likely to benefit from HER2-directed therapies through informed patient selection strategies.

A review of recent clinical trial results for emerging HER2-directed therapies, including SOHO-01, inetetamab/pyrotinib, and BEAMION Lung-01, and their potential impact on the future treatment landscape for HER2-positive NSCLC.

An exploration of emerging strategies to overcome resistance to HER2-directed therapies based on ongoing research advancements.

Dr Heymach real-world outcomes versus clinical trials for HER2-positive NSCLC and the management of common adverse events associated with HER2-directed therapies.

Paul Feuerstadt, MD, FACG, AGAF, discusses how testing for Clostridioides difficile is recommended for hospitalized patients or outpatients with new-onset, unexplained diarrhea who have risk factors such as recent antibiotic use, hospitalization, or older age, and how empiric treatment should be initiated while awaiting test results if there is high clinical suspension.

The panelist discusses how antibiotics are paradoxically both the primary treatment for Clostridioides difficile infections and a major risk factor for recurrence since they disrupt the protective gut microbiome, which led to the development of alternative therapies like fecal microbiota transplantation to restore microbial balance and prevent reinfection.

For some patients with myasthenia gravis (MG), activity and sleep were associated with reported fatigue and symptom levels.

Social isolation significantly increases the risk of mortality in patients with chronic obstructive pulmonary disease (COPD), highlighting the need for targeted interventions to address this issue.

Patients with locally advanced hepatocellular carcinoma (HCC) who achieve a complete response after locoregional therapy and immunotherapy may be able to follow a watch-and-wait protocol.

Despite challenges such as high attrition rates and adverse events, the trial highlights the value of established therapies in improving outcomes, particularly in regions with limited access to chimeric antigen receptor T cells and bispecific antibodies.

If approved, the combination regimen would be the first FDA-approved treatment for adults with recurrent KRAS mutant low-grade serous ovarian cancer (LGSOC).

This multiyear follow-up of more than 3300 patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) who received ibrutinib—the longest study of its kind—confirms the agent’s efficacy as a salvage treatment but reveals new information about its impact in different subpopulations with varying clinical characteristics.

With approval, acoramaidis (Attruby; BridgeBio Pharma) becomes the first agent with a label specifying near-complete stabilization of transthyretin (TTR).

Adults with more unfavorable health-related social needs, such as unemployment or food insecurity, had a higher prevalence of low cardiovascular health, highlighting the importance of addressing social determinants to improve population health.

The increase in the global burden of interstitial lung disease (ILD) and pulmonary sarcoidosis had the greatest impact on countries with a high sociodemographic index.

For over 20 years, the Movember Foundation has used its mustache-growing campaign to raise awareness and funds for men's health issues, namely mental health and prostate and testicular cancers.

A presentation at the National Community Pharmacists Association Annual Meeting and Exposition focused on the latest on COVID-19 vaccination.

Initiating palliative care more than 3 months before death improves end-of-life outcomes for patients with ovarian cancer, highlighting the need for earlier interventions.

A new study aimed at exploring the relationship between obesity and multiple sclerosis severity using genetic data finds that higher BMI and other obesity measures were associated with increased disability progression in patients with MS.

For patients with chronic lymphocytic leukemia (CLL) treated previously with venetoclax and Bruton’s tyrosine kinase inhibitors, many more trials are needed to pinpoint the best next steps

Higher Life’s Essential 8 (LE8) scores, especially those reflecting lower nicotine exposure and better sleep health, are inversely associated with chronic obstructive pulmonary disease (COPD) risk, emphasizing the importance of cardiovascular health (CVH) in disease prevention.

This recent study highlights key risk factors for rheumatoid arthritis–associated interstitial lung disease (RA-ILD), emphasizing the importance of early screening to improve diagnosis and patient outcomes.